Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. 1991

I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
Department of Ophthalmology, Hôpital Pitié-Salpêtrière, Paris, France.

Forty-four patients with acquired immune deficiency syndrome with cytomegalovirus (CMV) retinitis (64 eyes) intolerant of or refusing systemic antiviral therapy received 710 intravitreal injections of ganciclovir at the dosage of 400 micrograms per injection. The patients were followed for a mean period of 9 weeks. Induction therapy consisted of two injections a week until healing. Maintenance therapy consisted of one injection a week until relapse. All but 1 of 53 induction courses led to cicatrization, after a mean of 6.6 injections. In 54 maintenance courses, the 8-week relapse rate was 53%. During intravitreal therapy, involvement of the fellow eye occurred in 11% of the patients and CMV infection developed in a nonocular site in 16% of the patients. Five retinal detachments and two intravitreal hemorrhages occurred. No endophthalmitis or cataract was noted. Intravitreal ganciclovir appears to be a safe and effective alternative in patients intolerant of intravenous anti-CMV drugs.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012163 Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12). Retinal Pigment Epithelial Detachment,Detachment, Retinal,Detachments, Retinal,Retinal Detachments
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency

Related Publications

I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
June 2001, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
April 1995, Ophthalmology,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
November 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
October 1999, Postgraduate medical journal,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
April 1996, Revista clinica espanola,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
June 1997, Ophthalmology,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
May 1990, Ophthalmology,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
May 1995, Australian and New Zealand journal of ophthalmology,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
January 1992, The Annals of pharmacotherapy,
I Cochereau-Massin, and P Lehoang, and M Lautier-Frau, and L Zazoun, and P Marcel, and M Robinet, and S Matheron, and C Katlama, and S Gharakhanian, and W Rozenbaum
January 1992, German journal of ophthalmology,
Copied contents to your clipboard!